Last reviewed · How we verify
Nozin
At a glance
| Generic name | Nozin |
|---|---|
| Also known as | Ethanol-based Intranasal Solution, Ethanol-based Nasal Sanitizer, Ethanol-containing Nasal Solution |
| Sponsor | Fred Hutchinson Cancer Center |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- Prevention of Respiratory Viruses Using Nozin in Stem Cell Transplant Recipients (PREV-NOSE Study) (Phase 1)
- Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® (NA)
- SHIELD (Staph Intervention for Effective Local Defense): An Open-label Randomized Controlled Trial to Assess Efficacy of a Sustained Intervention (Topical Antibiotics and Skin Antisepsis) to Decrease (Phase 4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nozin CI brief — competitive landscape report
- Nozin updates RSS · CI watch RSS
- Fred Hutchinson Cancer Center portfolio CI